Document is current
Any future updates will be listed below
-
Authors
Michalski, Arthur
Vincent-Delorme, Catherine
Demoulin-Alexikova, Silvia
Smol, Thomas
Felloni, Paul
Le Rouzic, Olivier
Perez, Thierry
Bautin, Nathalie
Wémeau, Lidwine
Balduyck, Malika
Zerimech, Farid
Pontana, François
Delsart, Pascal
Cailliau, Emeline
Chenivesse, Cécile
Valentin, Victor https://orcid.org/0000-0002-4870-3923
-
Funding
Funding for this research was provided by:
Santelys Association (Santelys Association)
- License Information
-
More Information
Article History
Received: 2 May 2025
Accepted: 25 September 2025
First Online: 5 November 2025
Declarations
:
: The study was approved by the Institutional Review Board Ouest II of Angers University Hospital (2022-A00972-41). Participants included in the study provided written informed consent.
: Yes.
: Abstract in a French congress : CPLF 2025 (24-26th January 2025 in Marseille) and in the ERS congress 2025 (27 September to 1 October 2025 in Amsterdam).
: Emphysema seems frequent in adult women with FLNA pathogenic variant encouraging a systematic screening and measures for lung protection including avoidance of passive smoking.
: AM declares personal fees from Sysmed. CV-D declares no conflict of interest. SD-A declares no conflict of interest. TS declares no conflict of interest. PF declares no conflict of interest. OLR declares personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GSK and Sanofi, congress support from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Grifols, GSK and LFB. TP declares personal fees from AstraZeneca, Chiesi, GSK, Sanofi-Regeneron, congress support from AstraZeneca, Boehringer-Ingelheim, Chiesi, Sanofi-Regeneron, Viatrys and research grants from AstraZeneca, GSK. NB declares personal fees from AstraZeneca, GSK and Sanofi, congress support from AstraZeneca, Chiesi, LFB, Menarini, SOS Oxygene. LW declares personal fees from Boehringer-Ingelheim, Daiichi-Sankyo, Pfizer, Sanofi, AstraZeneca, congress support from Boehringer-Ingelheim, SOS Oxygene, Sysmed. MB declares no conflict of interest. FZ declares no conflict of interest. FP declares no conflict of interest. PD declares no conflict of interest. EC declares no conflict of interest. CC declares personal fees from ALK-Abello, AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK, Sanofi-Regeneron, congress support from AstraZeneca, Boehringer-Ingelheim, Chiesi, Novartis, Sanofi and research grants from AstraZeneca, GSK, Novartis, Santelys. VV declares personal fees from Boehringer-Ingelheim and research grants from Santelys.
